Compare International Business Machines Corp (IBM) vs Organon & Co. Common Stock (OGN) Price & Performance

IBM trades at $227.88, up 0.38% with a bearish technical signal despite recent positive momentum. The company shows strong fundamentals with 2025 revenue of $67.54B and net income of $10.59B, representing a 15.52% margin. Recent earnings beat expectations in two of the last three quarters, while Q3 2026 results are pending. Analyst consensus is mixed with 47% buy ratings and a $255.50 price target, suggesting 12% upside potential from current levels.

IBM presents a balanced opportunity with solid profitability and AI consulting growth offset by cyclical mainframe weakness and negative cash flow trends. The stock's current valuation at 20.5x P/E appears reasonable given the company's pivot to high-margin hybrid cloud and AI services. Key risks include execution challenges in the AI transition and competitive pressures in the consulting space.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.